August 15th 2025

By Ailsa Colquhoun

Dapagliflozin to enter Category M in September

Dapagliflozin 5mg and 10mg tablets will move from Category C to Category M in the September 2025 Drug Tariff, according to Community Pharmacy England.

This comes after several manufacturers launched generic versions of dapagliflozin tablets following the recent ruling by the UK Court of Appeal to invalidate AstraZeneca’s patent for the brand Forxiga^®.

In September 2025, reimbursement of generically written prescriptions for dapagliflozin tablets will be based on the Category M prices published in the September 2025 Drug Tariff. The Category M prices are calculated using actual market data obtained from suppliers.

This addition comes outside the usual Category M quarterly cycle (which routinely runs quarterly in January, April, July, and October). Ahead of the Drug Tariff changes in September, dispensers are advised to review and manage their brand and generic stockholding of dapagliflozin tablets.

Currently, all branded and generically written prescriptions for dapagliflozin tablets are reimbursed in line with NHS list prices of the brand Forxiga. 

The September Drug Tariff will be published on NHSBSA’s website at the end of August (typically three working days before the 1st of September). All other July to September 2025 Category M prices will remain unchanged.